Litigation Details for Celgene Corporation v. Accord Healthcare Inc. (D. Del. 2023)

Celgene Corporation v. Accord Healthcare Inc. (D. Del. 2023)

Docket	1:23-cv-00424	Date Filed	2023-04-18
Court	District Court, D. Delaware	Date Terminated	2023-11-27
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	11,571,436
Link to Docket	External link to docket

Details for Celgene Corporation v. Accord Healthcare Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-04-18				External link to document

Celgene v. Accord Healthcare (1:23-cv-00424): Litigation Summary, Claims at Issue, and What It Signals for Generic/Copycat Risk

Last updated: July 23, 2026

Celgene Corporation v. Accord Healthcare Inc., case number 1:23-cv-00424, is pending in the U.S. District Court for the District of Delaware and targets patent infringement tied to Celgene’s branded medicines. The case posture, infringement theories, and the specific asserted patents determine the practical timeline for any Accord launch and the leverage point for settlement.

What is Celgene Corporation v. Accord Healthcare Inc. (1:23-cv-00424) about?

The litigation is a patent infringement action brought by Celgene against Accord Healthcare in the ANDA/generic landscape context. The dispute is structured around FDA generics entry risk and the Orange Book patent list that Celgene controls for the relevant product(s).

At a high level, these cases typically track:

• Accord’s filing of an ANDA and its Paragraph IV or other “generic carve-out” notice to Celgene.
• Celgene’s infringement allegations based on one or more U.S. patents covering the approved drug substance, formulation, method of use, or manufacturing.
• A statutory stay or loss of exclusivity dynamics depending on whether patents are found invalid/not infringed and the timing of district court and Federal Circuit decisions.

Practical outcome variable: the asserted patent set. If Celgene’s asserted claims include composition-of-matter or formulation protections, generic entry risk is higher and launch timing depends on final judgment or settlement with a meaningful “carve-out” date.

Which patents are asserted in Celgene v. Accord (1:23-cv-00424)?

No complete, case-specific asserted-patent list is provided in the prompt, and producing an accurate patent-by-patent summary would require pulling the complaint, infringement contentions, and the court docket for the exact asserted U.S. patent numbers.

Result: A precise claim chart level summary (independent claims, dependent claims, and theory of infringement) cannot be generated from the information available in the request.

What claims are Celgene alleging Accord infringes?

In ANDA-based Hatch-Waxman cases like Celgene v. Accord, infringement theories typically fall into one or more of the following buckets:

• Direct infringement based on the manufacture, use, sale, offer for sale, or importation of the ANDA product.
• Indirect infringement (inducement or contributory) based on labels, instructions, and intended use.
• Infringement of specific formulation limits, dosage strengths, release characteristics, or salt/crystal/solid-state forms (if the case involves formulation/solid-state patents).
• Method-of-use infringement if the asserted patents are tied to dosing regimens or therapeutic indications.

Case-specific analysis requirement: the infringement theories used in this exact matter are determined by the complaint and infringement contentions. Without the docket text for the asserted patents and claims, the analysis would not be accurate.

What is the procedural posture in 1:23-cv-00424?

A litigation “snapshot” requires docket-level facts such as:

• complaint filing date
• answer date
• Rule 12 motions
• claim construction schedule (Markman)
• infringement and invalidity contentions
• summary judgment motions
• trial setting or dismissal/settlement

The prompt does not provide any docket timeline. Without it, an accurate posture statement would risk stating incorrect dates, deadlines, or outcomes.

Result: A full procedural timeline cannot be stated reliably.

When does this case affect generic entry and Orange Book exclusivity timelines?

In Hatch-Waxman litigation, generic entry timing is driven by:

• Whether Accord’s ANDA triggered a 30-month stay (and when it expires).
• Whether Celgene’s asserted patents are adjudicated invalid and/or not infringed.
• Whether the Federal Circuit remands or affirms and the issuance of final judgment.
• Whether any settlement includes a payment-for-delay style component (not assumed, but settlement often includes an agreed launch/180-day exclusivity or “design-around” date).

Key dependency: the asserted patent types and their expiration dates. That data is not included in the prompt.

How do Paragraph IV notices typically map to this case?

Cases with a branded plaintiff and generic defendant usually align with a sequence:

1. Accord files an ANDA and certifies to Orange Book patents.
2. Accord serves notice challenging at least one patent as invalid and/or not infringed.
3. Celgene sues within statutory time.
4. Litigation proceeds and may include a statutory stay and then post-stay launch risk.

Case-specific mapping: requires the specific Orange Book patents listed for the drug at issue, the certification(s) in Accord’s filing, and the dates. Those are not provided.

What is the litigation significance for Accord’s ANDA strategy?

The strategic effects of Celgene v. Accord depend on whether Accord’s product is:

• “fully designed around” the asserted claim scope,
• using a different formulation or dosing approach to avoid infringement,
• or relying on invalidity defenses aimed at composition-of-matter/formulation patents.

In practice:

• If Celgene asserts broad composition-of-matter or formulation patents, Accord’s technical work must show clear non-infringement or strong obviousness/novelty invalidity positions.
• If Celgene’s case is narrow to method-of-use claims, label carve-outs and different indication/dosing strategies can reduce risk.

Case-specific conclusion not possible without asserted patent claims and Accord’s defenses.

How strong is Celgene’s patent estate in this matter?

Patent strength is assessed through:

• breadth of the asserted claims (independent vs dependent),
• prosecution history and claim construction risk,
• whether the patents have survived prior challenges,
• co-pending litigation across the same patent family,
• and whether expiration/terminal disclaimers shorten practical leverage.

But strength cannot be quantified without the actual patents asserted and any claim construction outcomes.

Result: No defensible strength scoring can be produced without patent identifiers and claim details.

What generic entry risks exist if Celgene loses?

If Celgene loses on key asserted patents:

• Accord may seek to launch promptly, subject to remaining unadjudicated patents and any other exclusivity blocks.
• Other generic applicants may leverage the same reasoning if their ANDAs include similar certifications and design choices.
• Remaining Orange Book patents can still block or delay entry depending on whether they are still asserted and whether they expire.

Again, this depends on which patents are asserted and whether they are all dismissed.

No patent identifiers supplied, so no launch-risk analysis can be anchored to facts.

Which settlements or consent judgments commonly resolve cases like this?

Many Hatch-Waxman matters resolve through:

• covenant not to sue,
• agreed “non-infringement” positions tied to specific label changes,
• stipulated dismissal with an agreed entry date,
• or a settlement that pairs an agreed launch date with a technical “design around” and sometimes license terms.

No settlement terms are provided in the prompt, so the case cannot be summarized in a facts-based way.

What FDA and regulatory status issues are implicated?

The FDA-facing impacts typically include:

• whether Accord’s ANDA is eligible for approval during or after litigation,
• whether any patent challenges affect approval timing,
• and whether label changes are required to avoid method-of-use infringement.

But regulatory status requires:

• the specific NDA/ANDA product,
• Orange Book listing(s),
• and any FDA approvals or tentative approval dates.

Those are not in the request.

---

Key Takeaways

• Celgene v. Accord (1:23-cv-00424) is an ANDA-linked patent infringement action; business impact turns on the asserted patent list and the litigation schedule.
• A patent-by-patent litigation analysis (claims, validity defenses, and non-infringement theories) cannot be completed without the asserted U.S. patents and docket timeline.
• Generic launch timing, stay expiration impact, and settlement leverage require the Orange Book patent identifiers tied to the relevant drug and Accord’s certification details.

---

FAQs

1. How does a 30-month stay work in Hatch-Waxman cases like Celgene v. Accord?
2. What happens if the asserted patents include both formulation and method-of-use claims?
3. Can a label carve-out avoid method-of-use infringement in ANDA litigation?
4. Do claim construction outcomes usually decide Celgene vs. generic disputes, or does summary judgment dominate?
5. How do Federal Circuit rulings change generic entry timelines after a district court decision?

---

References

No sources are provided in the prompt to cite.